A Phase I/II Study of Bavituximab and Sorafenib In Patients With Advanced Hepatocellular Carcinoma
The investigators are looking for men or women aged 18 years or older with hepatocellular
carcinoma not suitable for surgical resection or hepatic transplantation. Prior locoregional
therapy including but not limited to transarterial chemoembolization (TACE), radiofrequency
ablation (RFA) or ethanol injection is allowed as long as the treatment was 4 weeks
previous. Patients must be Child-Pugh A with no previous treatment with sorafenib or other
vascular endothelial growth factor (VEGF) inhibitors.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Safety as measured by the number of participants with adverse events.
The phase I component is expected to be complete within 3 months.
Adam C Yopp, MD
UT Southwestern Medical Center
United States: Food and Drug Administration
|Ut Southwestern Medical Center||Dallas, Texas 75390|